Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor

Daisuke Yasuda, Akihiro Yuasa, Rika Obata, Mao Nakajima, Kyoko Takahashi, Tomoyuki Ohe, Yoshinobu Ichimura, Masaaki Komatsu, Masayuki Yamamoto, Riyo Imamura, Hirotatsu Kojima, Takayoshi Okabe, Tetsuo Nagano, Tadahiko Mashino

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Keap1-Nrf2 system is an attractive target for drug discovery regarding various unmet medical needs. Only covalent inhibitors for protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 have been approved or are under clinical trials, but such electrophilic compounds lack selectivity. Therefore, specific non-covalent Keap1-Nrf2 PPI inhibitors are expected to be safer Nrf2 activators. We found a novel class of non-covalent Keap1-Nrf2 PPI inhibitor that has a benzo[g]indole skeleton and an indole-3-hydroxamic acid moiety and that exhibits significant PPI inhibitory activity. Additionally, the benzo[g]indole-3-carbohydrazide derivatives were newly prepared. The benzo[g]indole derivatives showed a stronger Keap1-Nrf2 PPI inhibitory activity than Cpd16, a previously reported non-covalent PPI inhibitor. Moreover, most of the PPI inhibitors showed a high metabolic stability in a human microsome system with a low cytotoxicity against HepG2 cell lines, which suggests that novel benzo[g]indole-type Keap1-Nrf2 PPI inhibitors are expected to be biological tools or lead compounds for Nrf2 activators.

Original languageEnglish
Pages (from-to)5006-5009
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume27
Issue number22
DOIs
Publication statusPublished - 2017 Nov 15

Fingerprint

Indoles
Proteins
Hydroxamic Acids
Lead compounds
Derivatives
Hep G2 Cells
Drug Discovery

Keywords

  • High-throughput screening
  • Keap1
  • Metabolic stability
  • Nrf2
  • Protein-protein interaction inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor. / Yasuda, Daisuke; Yuasa, Akihiro; Obata, Rika; Nakajima, Mao; Takahashi, Kyoko; Ohe, Tomoyuki; Ichimura, Yoshinobu; Komatsu, Masaaki; Yamamoto, Masayuki; Imamura, Riyo; Kojima, Hirotatsu; Okabe, Takayoshi; Nagano, Tetsuo; Mashino, Tadahiko.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 27, No. 22, 15.11.2017, p. 5006-5009.

Research output: Contribution to journalArticle

Yasuda, D, Yuasa, A, Obata, R, Nakajima, M, Takahashi, K, Ohe, T, Ichimura, Y, Komatsu, M, Yamamoto, M, Imamura, R, Kojima, H, Okabe, T, Nagano, T & Mashino, T 2017, 'Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor', Bioorganic and Medicinal Chemistry Letters, vol. 27, no. 22, pp. 5006-5009. https://doi.org/10.1016/j.bmcl.2017.10.008
Yasuda, Daisuke ; Yuasa, Akihiro ; Obata, Rika ; Nakajima, Mao ; Takahashi, Kyoko ; Ohe, Tomoyuki ; Ichimura, Yoshinobu ; Komatsu, Masaaki ; Yamamoto, Masayuki ; Imamura, Riyo ; Kojima, Hirotatsu ; Okabe, Takayoshi ; Nagano, Tetsuo ; Mashino, Tadahiko. / Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor. In: Bioorganic and Medicinal Chemistry Letters. 2017 ; Vol. 27, No. 22. pp. 5006-5009.
@article{ffbfe540daf8444f8c9415ddd4dbbdd2,
title = "Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor",
abstract = "The Keap1-Nrf2 system is an attractive target for drug discovery regarding various unmet medical needs. Only covalent inhibitors for protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 have been approved or are under clinical trials, but such electrophilic compounds lack selectivity. Therefore, specific non-covalent Keap1-Nrf2 PPI inhibitors are expected to be safer Nrf2 activators. We found a novel class of non-covalent Keap1-Nrf2 PPI inhibitor that has a benzo[g]indole skeleton and an indole-3-hydroxamic acid moiety and that exhibits significant PPI inhibitory activity. Additionally, the benzo[g]indole-3-carbohydrazide derivatives were newly prepared. The benzo[g]indole derivatives showed a stronger Keap1-Nrf2 PPI inhibitory activity than Cpd16, a previously reported non-covalent PPI inhibitor. Moreover, most of the PPI inhibitors showed a high metabolic stability in a human microsome system with a low cytotoxicity against HepG2 cell lines, which suggests that novel benzo[g]indole-type Keap1-Nrf2 PPI inhibitors are expected to be biological tools or lead compounds for Nrf2 activators.",
keywords = "High-throughput screening, Keap1, Metabolic stability, Nrf2, Protein-protein interaction inhibitor",
author = "Daisuke Yasuda and Akihiro Yuasa and Rika Obata and Mao Nakajima and Kyoko Takahashi and Tomoyuki Ohe and Yoshinobu Ichimura and Masaaki Komatsu and Masayuki Yamamoto and Riyo Imamura and Hirotatsu Kojima and Takayoshi Okabe and Tetsuo Nagano and Tadahiko Mashino",
year = "2017",
month = "11",
day = "15",
doi = "10.1016/j.bmcl.2017.10.008",
language = "English",
volume = "27",
pages = "5006--5009",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "22",

}

TY - JOUR

T1 - Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor

AU - Yasuda, Daisuke

AU - Yuasa, Akihiro

AU - Obata, Rika

AU - Nakajima, Mao

AU - Takahashi, Kyoko

AU - Ohe, Tomoyuki

AU - Ichimura, Yoshinobu

AU - Komatsu, Masaaki

AU - Yamamoto, Masayuki

AU - Imamura, Riyo

AU - Kojima, Hirotatsu

AU - Okabe, Takayoshi

AU - Nagano, Tetsuo

AU - Mashino, Tadahiko

PY - 2017/11/15

Y1 - 2017/11/15

N2 - The Keap1-Nrf2 system is an attractive target for drug discovery regarding various unmet medical needs. Only covalent inhibitors for protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 have been approved or are under clinical trials, but such electrophilic compounds lack selectivity. Therefore, specific non-covalent Keap1-Nrf2 PPI inhibitors are expected to be safer Nrf2 activators. We found a novel class of non-covalent Keap1-Nrf2 PPI inhibitor that has a benzo[g]indole skeleton and an indole-3-hydroxamic acid moiety and that exhibits significant PPI inhibitory activity. Additionally, the benzo[g]indole-3-carbohydrazide derivatives were newly prepared. The benzo[g]indole derivatives showed a stronger Keap1-Nrf2 PPI inhibitory activity than Cpd16, a previously reported non-covalent PPI inhibitor. Moreover, most of the PPI inhibitors showed a high metabolic stability in a human microsome system with a low cytotoxicity against HepG2 cell lines, which suggests that novel benzo[g]indole-type Keap1-Nrf2 PPI inhibitors are expected to be biological tools or lead compounds for Nrf2 activators.

AB - The Keap1-Nrf2 system is an attractive target for drug discovery regarding various unmet medical needs. Only covalent inhibitors for protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 have been approved or are under clinical trials, but such electrophilic compounds lack selectivity. Therefore, specific non-covalent Keap1-Nrf2 PPI inhibitors are expected to be safer Nrf2 activators. We found a novel class of non-covalent Keap1-Nrf2 PPI inhibitor that has a benzo[g]indole skeleton and an indole-3-hydroxamic acid moiety and that exhibits significant PPI inhibitory activity. Additionally, the benzo[g]indole-3-carbohydrazide derivatives were newly prepared. The benzo[g]indole derivatives showed a stronger Keap1-Nrf2 PPI inhibitory activity than Cpd16, a previously reported non-covalent PPI inhibitor. Moreover, most of the PPI inhibitors showed a high metabolic stability in a human microsome system with a low cytotoxicity against HepG2 cell lines, which suggests that novel benzo[g]indole-type Keap1-Nrf2 PPI inhibitors are expected to be biological tools or lead compounds for Nrf2 activators.

KW - High-throughput screening

KW - Keap1

KW - Metabolic stability

KW - Nrf2

KW - Protein-protein interaction inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85031426399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031426399&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2017.10.008

DO - 10.1016/j.bmcl.2017.10.008

M3 - Article

VL - 27

SP - 5006

EP - 5009

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 22

ER -